A Changing Of The Guard At Merck R&D As Perlmutter Succeeds Kim
Amid growing concern over the quality of Merck’s late-stage pipeline, CEO Frazier made a decisive move to change the R&D leadership; Former Amgen R&D head Perlmutter will succeed Merck Research Laboratories President Kim in April.
You may also be interested in...
Pfizer and Merck have more than a deal on a diabetes candidate in common as both companies saw foreign exchange and patent expiries hit the bottom line in the first quarter and see emerging markets as key growth drivers this year.
The big biotech is investing heavily in two late-stage drugs – one for high cholesterol and the other for osteoporosis – that will test its ability to expand its specialty marketing savvy into primary care markets. Denosumab, launched in 2010 for osteoporosis under the brand name Prolia, was a first step, but investors see bigger opportunities ahead.
Merck insists it is committed to its cardiovascular franchise, but the company has had to halt the development of several CV assets and has been plagued by poor trial results for others.